Protocol Ledger

NCT04111978 · Phase III · RECRUITING

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Interventional Phase III clinical trial protocol NCT04111978 sponsored by Swiss GO Trial Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-05 Enrollment: 540 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04111978
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)540 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04111978
Protocol FieldVerified Registry Value
NCT IdentifierNCT04111978
Consolidated Lead SponsorSwiss GO Trial Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment540 participants (ESTIMATED)
Registered Start Date2020-11-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04111978
Hospital Research SiteLocationSite Profile
Medizinische Universität WienVienna, AustriaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI